

Exhibit A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449PTD

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

--	--

Complete if Known

Application Number	09/892,613
--------------------	------------

Filing Date	June 27, 2001
-------------	---------------

First Named Inventor	LEUNG, Shawn Shui-on
----------------------	----------------------

First Named Inventor	LEU
Art Unit	1643

7th Unit	1643
Examiner Name	R. ANCHARD, David

Examiner Name	BLANC
Attorney Docket Number	655-US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code* Number* Word Code* (if known)	MM-DD-YYYY			
	1	WO 97/34632 A	09-25-1997	Laung, et al.		
	2	WO 98/41641 A	09-24-1998	Fitzgerald, et al.		
	3	WO 99/55389 A	11-04-1999	Taylor, et al.		
	4	DE 4225853 A1	02-10-1994	Soomann, et al.		

Examiner
Signature

Date
Considered

* EXAMINER: Indicate if reference considered, whether or not citation is in conformance with MPEP 809. Draw and through citation is not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). ** See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *** Enter Office that issued the document, by the two-letter code (WFO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **** Draw of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ***** Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1460, Alexandria, VA 22313-1460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Exhibit B

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

1

Complete if Known

Application Number	09/892,613
Filing Date	June 27, 2001
First Named Inventor	LEUNG, Shawn Shui-on
Art Unit	1643
Examiner Name	BLANCHARD, David J.
Attorney Docket Number	655-US

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	5	Lewis, et al. "Generation of humanized monoclonal antibodies by 'best fit' framework selection and recombinant polymerase chain reaction" Year Immunology, Vol. 7, 110-118, 1993	
	6	Roguska, et al. "A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing" Protein Engineering, Vol. 8, 895-904, 1996	
	7	Singer, et al. "Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences" J. Immunol., Vol. 150, 2844-2857, 1993	
	8	Hamilton, et al. "A humanized antibody against Human Cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections" J. Infect. Diseases, Vol. 176, 59-68, 1997	
	9	Rachmann, et al. "Reshaping human antibodies for therapy" Nature, Vol. 332, 323-327, 1996	
	10	Rosok, et al. "A combinatorial library strategy for the rapid humanization of anticardiorne BR96 Fab" J. Biol. Chem., Vol. 271, 22611-22618, 1996	
	11	Shearman, et al. "Construction, expression and characterization of humanized antibodies directed against the human alphabeta T cell receptor" J. Immunol., Vol. 147, 4368-4373, 1991	
	12	January 30, 2007 Supplementary European Search Report from the European Patent Office for European Patent Application No. EP 02734771, filed January 28, 2004.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20521.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.